Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9476Triple Negative Breast Neoplasms 635Neoplasms 413Lung Neoplasms 342Prostatic Neoplasms 321Ovarian Neoplasms 299Colorectal Neoplasms 289Neoplasm Metastasis 280Motor Activity 267Carcinoma, Intraductal, Noninfiltrating 231Colonic Neoplasms 193Breast Neoplasms, Male 172Lymphedema 170Melanoma 158Pancreatic Neoplasms 152Breast Carcinoma In Situ 151Carcinoma, Non-Small-Cell Lung 149Uterine Cervical Neoplasms 144Fatigue 140Head and Neck Neoplasms 132Pain 122Breast Cancer Female 122Brain Neoplasms 118Stomach Neoplasms 117Sarcoma 106Depression 105Breast Cancer Lymphedema 101Anxiety Disorders 101Lymphoma 96Cardiotoxicity 89

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2 Overexpression × Breast × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡